MANKIND PHARMA LIMITED Fair Value
MANKIND · Healthcare · Current price ₹2,366.2
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹406 | 13% ROE fading to 13% over ~10 yrs, on ₹395 book |
| Relative P/E | ₹1,812 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹642 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹2,739 | Street consensus 12-month target price |
Is MANKIND PHARMA LIMITED undervalued?
DocStoX estimates the fair value of MANKIND PHARMA LIMITED at ₹1,179 per share, versus the current market price of ₹2,366. That puts the stock about -50.2% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹406), Relative P/E (₹1,812), Graham floor (₹642), Analyst target (₹2,739). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹406 (bear) to ₹1,179 (base) to ₹2,739 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on MANKIND PHARMA LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.